

# Salman Otoukesh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9646879/publications.pdf>

Version: 2024-02-01

12  
papers

97  
citations

1937685

4  
h-index

1474206

9  
g-index

12  
all docs

12  
docs citations

12  
times ranked

55  
citing authors

#	ARTICLE	IF	CITATIONS
1	Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. <i>Cancer</i> , 2022, 128, 529-535.	4.1	17
2	Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 111.e1-111.e8.	1.2	16
3	The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 2754-2756.	1.3	2
4	Refractory primary autoimmune myelofibrosis treated with ruxolitinib. <i>American Journal of Hematology</i> , 2021, 96, E283-E285.	4.1	3
5	Treatment of allosensitized patients receiving allogeneic transplantation. <i>Blood Advances</i> , 2021, 5, 4031-4043.	5.2	32
6	Current and Emerging Therapies for Acute Myeloid Leukemia. <i>Cancer Treatment and Research</i> , 2021, 181, 57-73.	0.5	2
7	Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias. <i>Blood</i> , 2021, 138, 3430-3430.	1.4	2
8	Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. <i>Bone Marrow Transplantation</i> , 2021, , .	2.4	2
9	The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement. <i>Leukemia and Lymphoma</i> , 2020, 61, 2020-2023.	1.3	15
10	Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide. <i>Blood</i> , 2020, 136, 10-11.	1.4	0
11	The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies. <i>Leukemia Research</i> , 2019, 84, 106196.	0.8	5
12	Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis. <i>Blood</i> , 2019, 134, 4518-4518.	1.4	1